Novo Nordisk Forges Strategic Alliance to Bolster US Market Position

Novo Nordisk ends patent dispute with Hims & Hers, forming a deal to distribute Ozempic and Wegovy via telehealth. The firm also plans major 2027 price cuts for its obesity drugs.

Danish pharmaceutical leader Novo Nordisk has transformed a legal confrontation into a commercial partnership. The company has settled its patent infringement lawsuit against telehealth provider Hims & Hers Health, with the resolution paving the way for a new distribution agreement. This move signals a deliberate strategy by the obesity and diabetes treatment giant to strengthen its foothold in the crucial US market.

From Litigation to Collaboration

The core of the settlement involves Hims & Hers agreeing to offer Novo Nordisk's FDA-approved medications, Ozempic and Wegovy, through its digital healthcare platform. In return, Novo Nordisk has dropped its legal action, which was initiated after the telehealth firm announced plans to distribute a compounded version of semaglutid—the active ingredient in Wegovy.

As part of the deal, Hims & Hers will cease advertising for such non-approved, compounded alternatives. Current patients on its platform will be offered the opportunity to transition to the original, regulator-approved drugs. This partnership is expected to apply significant pressure to the grey market for compounded GLP-1 receptor agonist medications.

Navigating a Competitive Landscape with Price Strategy

This alliance comes at a time of intensifying competition in the obesity treatment sector. In response, Novo Nordisk has announced plans to reduce the list prices of its key GLP-1 drugs by up to 50% starting in 2027. With Wegovy currently priced at approximately $1,349 per month, such a reduction would represent a substantial market shift.

The company possesses considerable financial flexibility to execute this strategy. Its gross profit margin exceeds 82%, providing room for price adjustments without jeopardizing investments in new therapies and production capacity expansion.

Concurrently, Novo Nordisk is actively repurchasing its own shares. Between February 4 and March 6, 2026, the company bought back about 5.3 million of its B shares. This activity is part of a broader repurchase program authorized for up to 15 billion Danish kroner.

Share Performance and Investor Sentiment

Despite these strategic initiatives, Novo Nordisk's equity remains under pressure. Since the start of the year, the share price has declined by roughly 23%. Compared to its 52-week high of €74.12, the stock has lost more than half its value. The newly formed partnership with Hims & Hers and the announced 2027 pricing strategy are clear signals that management is proactively defending its market position. Whether these measures will be sufficient to restore investor confidence will be determined by the company's performance in the coming quarters.